Related Experiment Video
Updated: Jun 2, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
p53 mutations of lung cancer are not significantly affected by CYP1A1 or GSTM1 polymorphisms
T Oyama1, T Kawamoto, T Mizoue
1UNIV OCCUPAT & ENVIRONM HLTH,DEPT SURG 2,KITAKYUSHU,FUKUOKA 807,JAPAN. UNIV OCCUPAT & ENVIRONM HLTH,DEPT ENVIRONM HLTH,KITAKYUSHU,FUKUOKA 807,JAPAN. UNIV OCCUPAT & ENVIRONM HLTH,DEPT CLIN EPIDEMIOL,KITAKYUSHU,FUKUOKA 807,JAPAN. KYUSHU UNIV,SCH MED,DEPT SURG 2,FUKUOKA 810,JAPAN. AICHI CANC CTR,DEPT THORAC SURG,NAGOYA,AICHI 464,JAPAN.
Abstract:
Cytochrome p4501A1 gene (CYP1A1) and glutathione S-transferase mu gene (GSTM1) are involved in the metabolic activation or detoxification of environmental carcinogens including benzo[a]pyrene in tobacco smoke. Individuals with both Val/Val and C type of CYP1A1 (CYP1A1; Val/Val and CYP1A1; C) or homozygous null (-/-) genotype of GSTM1 gene (GSTM1; -/-) show increased susceptibility to lung cancer. The incidence of p53 gene mutations are related to the smoking index of the lung cancer patients. Therefore we determined genotypes of these enzymes and screened p53 gene mutations in 123 non-small cell lung cancer (NSCLC) patients. p53 gene mutations were found in 35% (43/123) of the patients. The incidence of p53 gene mutation CYP1A1; Val/Val (60.0%), CYP1A1; C (50.0%) tended to be higher than those of CYPIAI; Ile/Ile and Ile/Val (40.4%) or CYP1A1; A and B (40.5%). We conclude that the incidence of the p53 mutations does not seem to be significantly affected by only CYP1A1 or GSTM1 polymorphisms in lung cancer patients.
More Related Videos
04:56Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
Published on: December 30, 2025
06:21Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Related Concept Videos
Abnormal Proliferation
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Cancer Prevention
Some...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu